On February 22, 2017, Sonex Health announced the successful completion of the first ultrasound-guided carpal tunnel release procedure in the United States using the SX-One MicroKnife™. The SX-One MicroKnife™ is an ultra-low profile surgical device that allows physicians to perform Micro-invasive carpal tunnel release (CTR) surgery through a single micro-incision (4-5 mm) using ultrasound guidance.
All posts by Clay Wilemon
7D Surgical announced today that it has received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and a medical device license from Health Canada enabling the North American commercial launch of its innovative Machine-vision Image Guided Surgery (MIGS™) system for spine surgery, the 7D Surgical System. This breakthrough system is designed to simplify and speed up surgical workflow, increase surgeon control, eliminate intraoperative radiation, and deliver exceptional value.
Big Data. The term is ubiquitous in our culture and its importance was validated by the attendance of over 500 people at the leadoff panel during the OCTANe 2016 Medical Device and Investor Forum. The panel, titled “Using Big Data To Improve Patient Outcomes and Reimbursement” was hosted by DevicePharm CEO, Clay Wilemon.
Much-anticipated breast cancer results from the prospective, randomized clinical study known as MINDACT were published in the August 24, 2016 edition of the New England Journal of Medicine. The MINDACT study evaluated the MammaPrint® 70-Gene Breast Cancer Recurrence Assay in 6,693 patients to determine its ability to help physicians identify which early-stage breast cancer patients would, and would not, likely benefit from chemotherapy.
UK Trade & Investment — the business development arm of the British Consulate — invited DevicePharm CEO & Chief Strategy Officer, Clay Wilemon, to present to UK medical firms during a February conference.
Healthcare reform is changing the way that healthcare marketers think about everything from clinical trials to product launches. New payment models, new delivery models, and HEOR mandates are all creating major changes in marketing focus for medical device, biotech, pharmaceutical, and medical diagnostics companies.
OCTANe launched the 10th annual Medical Device & Investor Forum on November 2, 2015 at the Hotel Irvine by introducing an expanded vision for Orange County’s technology industry accelerator. The presentation included an introduction of the expanded brand scope and new branding elements by DevicePharm CEO & Chief Strategy Officer, Clay Wilemon.
What if you could focus your marketing plans and messaging only on the people who were actually going to buy your product or service?” This was the question posed by Clay Wilemon, DevicePharm CEO & Chief Strategy Officer, to an enthusiastic audience in San Diego during the September Device Alliance meeting.
The reality is that using predictive analytics in market research is providing a more precise way of targeting, messaging, and selling to the customers who are actually going to buy your products.
The OCTANe Ophthalmology Summit is a unique convocation of ophthalmology executives, researchers, entrepreneurs, investors, physicians, and surgeons. Held each year in Orange County, CA, the global ophthalmic industry hub, this event provides an important opportunity for innovators to gather and share ideas about the growth and future of this important medical industry segment.
A recent Medical Marketing & Media article indicated that 55% of pharmaceutical companies are either partially or strongly dissatisfied with their multi-channel marketing efforts. The article went on to quote that, “When integrated across an organization and executed properly, multi-channel campaigns can boost top-line growth by more than 10% and reduce overall promotional costs by 10% to 25%.” So where is the disconnect between multi-channel marketing effectiveness and multi-channel marketing dissatisfaction?